Mutation screening in patients for familial hypercholesterolaemia (ADH)

Clinical Genetics

Volumn 77, Issue 1, 2010, Pages 97-99

  Taylor, A ^a   Patel, K ^a   Tsedeke, J ^a   Humphries, S E ^b   Norbury, G ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; DNA; LOW DENSITY LIPOPROTEIN RECEPTOR;

CONTROLLED STUDY; DIAGNOSTIC VALUE; FAMILIAL HYPERCHOLESTEROLEMIA; FRAMESHIFT MUTATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC SCREENING; HUMAN; LETTER; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY ANALYSIS; UNITED KINGDOM;

GENETIC TESTING; GREAT BRITAIN; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; RECEPTORS, LDL;

EID: 73049111746     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01279.x     Document Type: Letter

References (15)

1. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. Br Med J 2008, 337:509-510.
2. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of under diagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000, 321:148.
3. Marks D, Thorogood M, Farrer JM, Humphries SE. Census of clinics providing specialist lipid services in the United Kingdom. J Public Health (Oxf) 2004, 26:353-354.
4. Varret M, Abifadel M, Rabes JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008, 73:1-13.
5. Wierzbicki AS, Graham CA, Young IS, Nicholls DP. Familial combined hyperlipidaemia: under-defined and under-diagnosed? Curr Vasc Pharmacol 2008, 6(1):13-22.
6. Laitinen J, Samarut J, Holtta E. A nontoxic and versatile protein salting-out method for isolation of DNA. Biotechniques 1994, 17:322-320.
7. http://www.tepnel.com/uploads/File/downloads/31238_TD_FH20_datasheet_MR.pdf, accessed on: 2009
8. Taylor A, Tabrah S, Wang D. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia. Clin Genet 2007, 71:561-568.
9. Taylor A, Martin B, Wang D, Patel K, Humphries SE, Norbury G. Multiplex ligation-dependent probe amplification analysis to screen for deletions and duplications of the LDLR gene in patients with familial hypercholesterolaemia. Clin Genet 2009, 76:69-75.
10. Betteridge DJ, Broome K, Durrington PN. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999, 142:105-112.
11. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008, 72:485-498.
12. Humphries SE, Whittall RA, Hubbart CS. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
13. Tosi I, Toledo-Leiva P, Neuwirth C, Naoumova RP, Soutar AK. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 2007, 194:102-111.
14. Graham CA, McIlhatton BP, Kirk CW. Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 2005, 182:331-340.
15. Capalbo C, Ricevuto E, Vestri A. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. Ann Oncol 2006, 7(Suppl. 17):34-40. vii,